Cigna Corporation
CI Healthcare Medical - Healthcare Plans NYSE
$279.91
+$0.71 (+0.25%)
Open: $279.52 | High: $280.14 | Low: $277.10 | Prev Close: $279.20
Market Cap: $74.77B
Volume: 531K | Avg: 2.0M
Last updated: January 26, 2026 at 06:01 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 505
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 12.39 |
| P/B Ratio | 1.78 |
| P/S Ratio | 0.28 |
| EPS | $22.59 |
| Beta | 0.27 |
| Shares Outstanding | 267.13M |
| 52-Week High | $350.00 |
| 52-Week Low | $239.51 |
| SMA 50 | $274.03 |
| SMA 200 | $296.95 |
| Dividend Yield | 2.16% |
| Annual Dividend | $6.04 |
| Next Earnings | February 05, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 10.0% |
| Operating Margin | 3.4% |
| Net Margin | 2.3% |
| ROE | 15.1% |
| ROA | 3.9% |
| Debt/Equity | 0.81 |
| Current Ratio | 0.83 |
| Quick Ratio | 0.73 |
Balance Sheet
| Total Assets | $155.88B |
| Total Liabilities | $114.64B |
| Total Equity | $41.03B |
|
|
|
| Cash | $7.55B |
| Total Debt | $31.97B |
| Net Debt | $24.42B |
Income Statement
| Revenue | $247.12B |
| Gross Profit | $25.96B |
| Operating Income | $9.42B |
| Net Income | $3.43B |
|
|
|
| EBITDA | $11.45B |
| Revenue/Share | $1007.32 |
Cash Flow
| Operating CF | $10.36B |
| CapEx | $1.41B |
| Free Cash Flow | $8.96B |
|
|
|
| Book Value/Share | $157.84 |
| Tangible Book/Share | $-119.79 |
| Equity/Share | $157.05 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Healthcare)
| Metric | CI | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 12.39 | 35.82 | 16% |
| P/B Ratio | 1.78 | 0.23 | 22% |
| ROE (%) | 15.06% | 14.15% | 50% |
| Net Margin (%) | 2.29% | 9.81% | 20% |
| Stock Score | 505 | 467.0 | 61% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CI | $279.91 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the CI stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| CI | FTC Delays Drug Middlemen Case While Talks Move Forward | Neutral | feeds.benzinga.com | Read More |
| CI | Austin Private Wealth, LLC Buys 121 Shares of The Cigna Group (CI) | Neutral | gurufocus.com | Read More |
| CI | The Cigna Group Renews Support for Achilles International's Freedom Team, Empowering Wounded Veterans and Adaptive Athletes | Neutral | prnewswire.com | Read More |
| CI | Conning Inc. Boosts Stake in Cigna Group $CI | Neutral | defenseworld.net | Read More |
| CI | The Cigna Group's Fourth Quarter 2025 Earnings Release Details | Neutral | prnewswire.com | Read More |
Recent Insider Trading
No recent insider trading data available for CI
Company Information
The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
| CEO | David Michael Cordani |
| Employees | 71295 |
| Country | US |
| IPO Date | 1982-03-31 |
| Exchange | NYSE |
| Website | https://www.cigna.com |
| Sector | Healthcare |
| Industry | Medical - Healthcare Plans |
Similar Stocks (Healthcare - Medical - Healthcare Plans)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category